ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΈΠ½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠΏΠ°ΡΠΈΠΈ Ρ ΡΡΠ°Π½ΡΠ³Π΅Π½Π½ΡΡ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ Ρ ΡΠ΅Π»ΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ° Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π½Π΅ΠΉΡΠΎΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡΠ½ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ²
ΠΡ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°ΡΡ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΡΡ Π³Π°ΠΌΠΌΠ°-ΡΠΈΠ½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠΏΠ°ΡΠΈΡ, Π²ΠΎΡΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΡΡ Π² ΡΡΠ°Π½ΡΠ³Π΅Π½Π½ΡΡ ΠΌΡΡΠ°Ρ Π»ΠΈΠ½ΠΈΠΈ Π’Π¬Ρ1ΡΡ8Π ΠΊΠ»ΡΡΠ΅Π²ΡΠ΅ Π·Π²Π΅Π½ΡΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° Π½Π΅ΠΉΡΠΎΠ΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° Ρ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠ²Π½ΡΠΌ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΠ΅ΠΌ Π±Π΅Π»ΠΊΠΎΠ²ΡΡ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΠΉ Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ°: Π°) ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΡΡ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΈ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΡ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΡΡΠ°Π½ΡΠ³Π΅Π½Π½ΡΡ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ ΡΠΊΠ·ΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ Π³Π°ΠΌΠΌΠ°-ΡΠΈΠ½ΡΠΊΠ»Π΅ΠΈΠ½Π°Π±… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M. and Bonini N.M. Chap-erone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Il Science 2002. — T.295(5556). — C.865−8.
- Bachurin S.O., Shevtsova E.P., Kireeva E.G., Oxenkrug G.F. and Sablin S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. // Ann N Y Acad Sei 2003. — T.993. — C.334−44- discussion 345−9.
- Bar-On P., Rockenstein E., Adame A., Ho G., Hashimoto M. and Masliah E. Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy. // JNeurochem — 2006. T.98(4). — C.1032−45.
- Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. // Acta Neuropathol — 2006. — T. l 12(3). C.237−51.
- Beyer K. and Ariza A. Protein aggregation mechanisms in synucleinopathies: commonalities and differences. // J Neuropathol Exp Neurol — 2007. -T.66(l 1). C.965−74.
- Beyer K., Domingo-Sabat M. and Ariza A. Molecular pathology of lewy body diseases. //Int J Mol Sei-2009. T. 10(3). — C.724−45.
- Buchman V.L., Hunter H.J., Pinon L.G., Thompson J., Privalova E.M., Ninkina N.N. and Davies A.M. Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. // JNeurosci — 1998. -T.l 8(22). C.9335−41.
- Cabin D.E., Gispert-Sanchez S., Murphy D., Auburger G., Myers R.R. and Nussbaum R.L. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. // Neurobiol Aging 2005. — T.26(l). — C.25−35.
- Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M. and Sudhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. // Cell 2005. — T. 123(3). — C.383−96.
- Chen L., Thiruchelvam M.J., Madura K. and Richfield E.K. Proteasome dysfunction in aged human alpha-synuclein transgenic mice. // Neurobiol Dis -2006. T.23(l). — C.120−6.
- Chiba-Falek O. and Nussbaum R.L. Regulation of alpha-synuclein expression: implications for Parkinson’s disease. // Cold Spring Harb Symp Quant Biol2003. T.68. — C.409−15.
- Choi D.Y., Liu M., Hunter R.L., Cass W.A., Pandya J.D., Sullivan P.G., Shin E.J., Kim H.C., Gash D.M. and Bing G. Striatal neuroinflammation promotes Parkinsonism in rats. // PLoS One 2009. — T.4(5). — C. e5482.
- Dev K.K., Hofele K., Barbieri S., Buchman V.L. and van der Putten H. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. // Neuropharmacology 2003. — T.45(l). — C. 14−44.
- Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. // Pharmacol Ther 1999. — T.81(3). — C.163−221.
- Drolet R.E., Behrouz B., Lookingland K.J. and Goudreau J.L. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. // Neurotoxicology 2004. — T.25(5). — C.761−9.
- Duan Y., Gross R.A. and Sheu S.S. Ca2±dependent generation of mitochondrial reactive oxygen species serves as a signal for poly (ADP-ribose) polymerase-1 activation during glutamate excitotoxicity. II J Physiol 2007. -T.585(Pt 3). — C.741−58.
- Feany M.B. and Bender W.W. A Drosophila model of Parkinson’s, disease. // Nature — 2000. T.404(6776). — C394−8.
- Fink A.L. The aggregation and fibrillation of alpha-synuclein. // Acc Chem Res ~ 2006. T.39(9). — C.628−34.
- Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S. and Chesselet M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. // J Neurosci 2004. -T.24(42). — C.9434−40.
- Fortin D.L., Troyer M.D., Nakamura K., Kubo S., Anthony M.D. and Edwards R.H. Lipid rafts mediate the synaptic localization of alpha-synuclein. // J Neu-rosci 2004. — T.24(30). — C.6715−23.
- Frasier M., Walzer M., McCarthy L., Magnuson D., Lee J.M., Haas C., Kahle P. and Wolozin B. Tau phosphorylation increases in symptomatic mice overex-pressing A30P alpha-synuclein. // Exp Neurol- 2005. T. 192(2). — C.274−87.
- Gallardo G., Schluter O.M. and Sudhof T.C. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. // Nat Neurosci 2008:-T.l 1(3).-C.301−8.
- Galvin J.E., Lee V.M. and Trojanowski J.Q. Synucleinopathies: clinical and pathological implications. // Arch Neurol 2001. — T.58(2). — C. 186−90.
- Gao H.M., Kotzbauer P.T., Uryu K., Leight S., Trojanowski J.Q. and Lee V.M. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. // J Neurosci 2008. — T.28(30). — C.7687−98.
- Gasser T. Update on the genetics of Parkinson’s disease. // Mov Disord 2007. -T.22 Suppl 17.-C.S343−50.
- George J.M. The synucleins. // Genome Biol 2002. — T.3(l). -C.reviews3002.1−3002.6.
- Giasson B.I., Duda J.E., Forman M.S., Lee V.M. and Trojanowski J.Q. Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. // Exp Neurol 2001. — T. 172(2). -C.354−62.
- Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q. and Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. // Neuron 2002. — T.34(4). — C.521−33.
- Goedert M. and Spillantini M.G. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. // Mol Psychiatry — 1998. T.3(6). — C.462−5.
- Grigorev V.V., Dranyi O.A. and Bachurin S.O. Comparative study of action mechanisms of dimebon and memantine on AMP A- and NMDA-subtypes glutamate receptors in rat cerebral neurons. // Bull Exp Biol Med 2003. -T. 136(5). — C.474−7.
- Hamamichi S., Rivas R.N., Knight A.L., Cao S., Caldwell K.A. and Caldwell
- G.A. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson’s disease model. // Proc Natl Acad Sci USA- 2008. T. 105(2). -C.728−33.
- Hashimoto M., Rockenstein E., Mante M., Mallory M. and Masliah E. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an antiparkinsonian factor. // Neuron 2001. — T.32(2). — C.213−23.
- Kahle P.J., Neumann M., Ozmen L. and Haass C. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson’s disease-associated protein. // Ann N Y Acad Sci 2000. — T.920. -C.33−41.
- Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van Der Putten H., Probst A., Kremmer E., Kretzschmar
- H.A. and Haass C. Subcellular localization of wild-type and Parkinson’s disease-associated mutant alpha -synuclein in human and transgenic mouse brain. // JNeurosci 2000. — T.20(17). — C.6365−73.
- Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Spooren W., Fuss
- B., Mallon B., Macklin W.B., Fujiwara H., Hasegawa M., Iwatsubo T., Kretzschmar H.A. and Haass C. Hyperphosphorylation and insolubility of al-pha-synuclein in transgenic mouse oligodendrocytes. II EMBO Rep — 2002. -T.3(6). C.583−8.
- Kaplan B., Ratner V. and Haas E. Alpha-synuclein: its biological function and role in neurodegenerative diseases. // J Mol Neurosci 2003. — T.20(2). — C.83−92. j
- Klein C. and Lohmann-Hedrich K. Impact of recent genetic findings in Parkinson’s disease. // Curr Opin Neurol 2007. — T.20(4). — C.453−64.
- Klivenyi P., Siwek D., Gardian G., Yang L., Starkov A., Cleren C., Ferrante R.J., Kowall N.W., Abeliovich A. and Beal M.F. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. // Neurobiol Dis 2006. — T.21(3).1. C.541−8.
- Klucken J., Shin Y., Masliah E., Hyman B.T. and McLean P.J. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. // J Biol Chem 2004. — T.279(24). — C.25 497−502.
- Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L. and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. // Nat Genet 1998. — T.18(2). -C.106−8.
- Lakso M., Vartiainen S., Moilanen A.M., Sirvio J., Thomas J.H., Nass R., Blakely R.D. and Wong G. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. // J Neurochem 2003. — T.86(l). — C. 165−72.
- Lavedan C. The synuclein family. // Genome Res 1998. — T.8(9). — C.871−80.
- Lee J.K., Tran T. and Tansey M.G. Neuroinflammation in Parkinson’s disease. // JNeuroimmune Pharmacol 2009. — T.4(4). — C.419−29.
- Lee J.T., Wheeler T.C., Li L. and Chin L.S. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. // Hum Mol Genet -2008. T.17(6). — C.906−17.
- Lermontova N.N., Lukoyanov N.V., Serkova T.P., Lukoyanova E.A. and Bachurin S.O. Dimebon improves learning in animals with experimental Alzheimer’s disease. // Bull Exp Biol Med 2000. — T. 129(6). — C.544−6.
- Lynch G. Memory enhancement: the search for mechanism-based drugs. // Nat Neurosci 2002. — T.5 Suppl. — C.1035−8.
- Manning-Bog A.B., McCormack A.L., Purisai M.G., Bolin L.M. and Di Monte D.A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. // J Neurosci 2003. — T.23(8). — C.3095−9.
- Marti M.J., Tolosa E. and Campdelacreu J. Clinical overview of the synuclei-nopathies. //MovDisord-2003. -T.18 Suppl 6. C. S21−7.
- Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L. and Lee M.K. Parkinson’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. // J Neurosci — 2006. T.26(l). — C.41−50.
- Melnikova I. Therapies for Alzheimer’s disease. // Nat Rev Drug Discov — 2007. T.6(5). — C.341−2.
- Morris R. Thy-1 in developing nervous tissue. // Dev Neurosci 1985. -T.7(3). — C.133−60.
- Neumann M., Kahle P.J., Giasson B.I., Ozmen L., Borroni E., Spooren W., Muller V., Odoy S., Fujiwara H., Hasegawa M., Iwatsubo T., Trojanowski J.Q.,
- Kretzschmar H.A. and Haass C. Misfolded proteinase K-resistant hyperphos-phorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. // J Clin Invest 2002. -T.l 10(10). -C. 1429−39.
- Ninkina N., Peters O., Millership S., Salem H., van der Putten H. and Buchman V.L. Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. U Hum Mol Genet -2009. T. l 8(10). — C. 1779−94.
- O’Neill M.J. and Dix S. AMPA receptor potentiators as cognitive enhancers. // IDrugs 2007. — T. 10(3). — C. 185−92. .
- O’Neill M.J. and Witkin J.M. AMPA receptor potentiators: application for depression and Parkinson’s disease. // Curr Drug Targets — 2007. — T.8(5). -C.603−20.
- Papachroni K., Ninkina N., Wanless J., Kalofoutis A.T., Gnuchev N.V. and Buchman V.L. Peripheral sensory neurons survive in the absence of alpha- and gamma-synucleins. IIJ Mol Neurosci- 2005. T.25(2). — C. 157−64.
- Papachroni K.K., Ninkina N., Papapanagiotou A., Hadjigeorgiou G.M., Xiro-merisiou G., Papadimitriou A., Kalofoutis A. and Buchman V.L. Autoantibodies to alpha-synuclein in inherited Parkinson’s disease. // J Neurochem — 2007. T.101(3). — C.749−56.
- Parsons C.G. and Gilling K. Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker. // Methods Mol Biol 2007. — T.403. — C. 15−36.
- Pendleton R.G., Parvez F., Sayed M. and Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson’s disease in Drosophila melanogaster. // J Pharmacol Exp Ther- 2002. T.300(l). — C.91−6.
- Periquet M., Fulga T., Myllykangas L., Schlossmacher M.G. and Feany M.B. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. // J Neurosci 2007. — T.27(12). — C.3338−46.
- Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmen L., Haid S., Okochi M., Haass C. and Schulz J.B. Sensitivity to MPTP is not increased in Parkinson’s disease-associated mutant alpha-synuclein transgenic mice. // J Neurochem -2001.-T.77(4).-C.l 181−4.
- Reddy P.H., Mao P. and Manczak M. Mitochondrial structural and functional dynamics in Huntington’s disease. // Brain Res Rev 2009. — T.61(l). — C.33−48.
- Riedel G., Piatt B. and Micheau J. Glutamate receptor function in learning and memory. // Behav Brain Res 2003. — T. 140(1−2). — C. l-47.
- Rothermel B.A. and Hill J.A. The heart of autophagy: deconstructing cardiac proteotoxicity. // Autophagy 2008. — T.4(7). — C.932−5.
- Sabbagh M.N. and Shill H.A. Latrepirdine, a potential novel treatment for Alzheimer’s disease and Huntington’s chorea. // Curr Opin Investig Drugs — 2010. -T.ll (l). -C.80−91.
- Sharon R., Bar-Joseph I., Frosch M.P., Walsh D.M., Hamilton J.A. and Selkoe D.J. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. // Neuron 2003. — T.37(4). — C.583−95.
- Skipper L., Liu J.J. and Tan E.K. Polymorphisms in candidate genes: implications for the current treatment of Parkinson’s disease. // Expert Opin Pharmaco-ther 2006. — T.7(7). — C.849−55.
- Skovronsky D.M., Lee V.M. and Trojanowski J.Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. // Annu Rev Pathol 2006. — T. 1. — C. 151 -70. .
- Song D.D., Shults C.W., Sisk A., Rockenstein E. and Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. // Exp Neurol 2004. — T. 186(2). — C. 158−72.
- Specht C.G. and Schoepfer R. Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. // BMC Neurosci 2001. — T.2(l). -C.ll.
- Specht C.G., Tigaret C.M., Rast G.F., Thalhammer A., Rudhard Y. and Schoepfer R. Subcellular localisation of recombinant alpha- and gamma-synuclein. // Mol Cell Neurosci 2005. — T.28(2). — C.326−34.
- Spillantini M.G. and Goedert M. The alpha-synucleinopathies: Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. // Ann N Y Acad Sci 2000. — T.920. — C. 16−27.
- Stefanova N., Kollensperger M., Hainzer M., Cenci A., Poewe W. and Wenning G.K. High dose levodopa therapy is not toxic in multiple system atrophy: experimental evidence. II Mov Disord-2007. T.22(7). — C.969−73.
- Stefanova N., Poewe W. and Wenning G.K. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. // Exp Neurol — 2007. —.
- Stichel C.C., Zhu X.R., Bader V., Linnartz B., Schmidt S. and Lubbert H. Mono- and double-mutant mouse models of Parkinson’s disease display severe mitochondrial damage. // Hum Mol Genet 2007. — T. 16(20). — C.3377−93.
- Strong M.J., Kesavapany S. and Pant H.C. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? // J Neuropathol Exp Neurol 2005. -T.64(8). — C.649−64.
- Su H. and Wang X. The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. // Cardiovasc Res T.85(2). — C.253−62.
- Tan E.K. and Skipper L.M. Pathogenic mutations in Parkinson disease. // Hum Mutat- 2007. T.28(7). — C.641−53.
- Thiruchelvam M.J., Powers J.M., Cory-Slechta D.A. and Richfield E.K. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. // Eur JNeurosci 2004. — T. 19(4). — C.845−54.
- Tofaris G.K., Garcia Reitbock P., Humby T., Lambourne S.L., O’Connell M., Ghetti B., Gossage H., Emson P.C., Wilkinson L.S., Goedert M. and Spillantini
- M.G. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein (l-120): implications for Lewy body disorders. // JNeurosci — 2006. T.26(15). -C.3942−50.
- Ustyugov A.A., Shelkovnikova T.A., Ninkina N.N. and Bachurin S.O. Dime-bon slows the progression of neurodegeneration^ in transgenic model of synu-cleinopathy. // Journal of Neurochemistry 2009. — T. 110(s 1). — C.42.
- Ustyugov A.A., Shelkovnikova T.A., Ninkina N.N. and Bachurin S.O. Synu-cleionapthy is tempered by Dimebon. // ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΡΠΈΠΌΠΏΠΎΠ·ΠΈΡΠΌΠ° «11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy», Geneva, Switzerland, — 2010. — C.81.
- Wakamatsu M., Iwata S., Funakoshi T. and Yoshimoto M. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson’s disease. // J Neurosci Res — 2008. T.86(3). -C.640−6.
- Wang L., Fleming S.M., Chesselet M.F. and Tache Y. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. // Neuroreport — 2008. — T.19(8). — C.873−6.
- Williams A., Jahreiss L., Sarkar S., Saiki S., Menzies F.M., Ravikumar B. and Rubinsztein D.C. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. // Curr Top Dev Biol — 2006. T.76. — C.89−101.
- Winner B., Lie D.C., Rockenstein E., Aigner R., Aigner L., Masliah E., Kuhn H.G. and Winkler J. Human wild-type alpha-synuclein impairs neurogenesis. // JNeuropathol Exp Neurol 2004. — T.63(l 1). — C. 1155−66.
- Winner B., Rockenstein E., Lie D.C., Aigner R., Mante M., Bogdahn U., Couil-lard-Despres S., Masliah E. and Winkler J. Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis. // Neurobiol Aging — 2007.
- Winner B., Rockenstein E., Lie D.C., Aigner R., Mante M., Bogdahn U., Couil-lard-Despres S., Masliah E. and Winkler J. Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis. // Neurobiol Aging 2008. — T.29(6). -C.913−25.
- Xun Z., Sowell R.A., Kaufman T.C. and Clemmer D.E. Protein expression in a Drosophila model of Parkinson’s disease. // JProteome Res — 2007. T.6(l). -C.348−57.
- Yavich L., Jakala P. and Tanila H. Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A3 OP transgenic mice. // JNeurochem 2006. — T.99(3). — C.724−32.
- Yavich L., Tanila H., Vepsalainen S. and Jakala P. Role of alpha-synuclein in presynaptic dopamine recruitment. // J Neurosci 2004. — T.24(49). -C.l 1165−70. -
- V. (Moscow, RU) (2001). Agent for treating neurodegenerative disorders. United States, Selena Pharmaceuticals, Inc. (San Francisco, CA).
- Zhou W., Milder J.B. and Freed C.R. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease. II J Biol Chem 2008. — T.283(15). -C.9863−70.
- ΠΠΈΠ½ΠΊΠΈΠ½Π° Π.Π., Π£ΡΡΡΠ³ΠΎΠ² A.A. and ΠΡΡ ΠΌΠ°Π½ B.JI. ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΈΠ½ΡΠΊΠ»Π΅ΡΠΈ-Π½ΠΎΠΏΠ°ΡΠΈΠΉ Π² Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈ ΠΌΠΎΠ΄ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ ΡΡΠΏΠ΅Ρ ΠΈ ΠΈ Π½Π΅ΡΠ΄Π°ΡΠΈ. // ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Π°Ρ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ — 2008. — Π’.42(5). — Π‘.840−855.